<DOC>
	<DOCNO>NCT02205073</DOCNO>
	<brief_summary>This single site , randomize , double-blind , three period cross-over , placebo-controlled , proof mechanism study healthy male subject . The study investigate whether directionality brain activity connectivity response intranasal vasopressin treatment similar early study explore effect short-term treatment RG7314 functional MRI pharmacodynamic marker . While scanner , participant ask perform face match task Theory Mind task , among assessment . Participants ' exposure study drug assess participant receive follow-up examination 1 4 week last dose .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Double-blind , Placebo-controlled Crossover Study RG7314 Potential Regulation Higher Brain Functions Healthy Male Participants : Proof Mechanism</brief_title>
	<detailed_description />
	<criteria>Righthanded , healthy nonsmoker male adult , 18 45 year age A body mass index 18 32 kg/m2 inclusive total weight range 50100 kg Participants partner childbearing potential must use 2 method contraception , one must barrier method duration study 90 day last dose In investigator 's opinion , subject deem appropriate participation study , capable follow study schedule assessment comply study restriction discontinuation prohibit medication pose undue risk participant History alcohol and/or substance abuse/dependence History relapse current psychiatric neurological disorder Participants , Investigator 's judgment , pose suicidal risk , subject history suicidal attempt behavior Positive result serology test HIV , Hepatitis B , hepatitis C viruses Confirmed ( e.g . 2 consecutive measurement ) clinically significant abnormality 12lead electrocardiogram ( ECG ) , include QTcF &gt; /= 450 millisecond Confirmed clinically significant abnormality vital sign , clinical chemistry and/or urinalysis Active stomach ulcer disease active gastrointestinal bleeding Personal family history ( first second degree relative ) cerebral aneurysm Personal history stroke traumatic head injury Confirmed clinically significant abnormality parameter hematology coagulation History coagulopathies , bleed disorder blood dyscrasias History hematological malignancy myelosuppression ( include iatrogenic ) . Contraindications MRI scan brain/head abnormality restrict MRI eligibility Fulfillment MRI contraindication standard radiography screening questionnaire Use prohibit medication within 2 week prior randomization , 5 halflives ( whichever longer ) Participation investigational drug study within 90 day prior randomization Donation loss blood 500 mL within three month prior randomization Chronic rhinitis , allergic rhinitis , nasal polyp nasal pathology may affect absorption intranasal AVP accord investigator judgment Concomitant disease , condition treatment might interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwilling unable comply follow lifestyle guideline : ( 1 ) participant abstain alcohol entire study participation ; ( 2 ) abstinence psychoactive agent drug abuse duration study period ; ( 3 ) participant abstain unusual strenuous exercise throughout entire study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>